Kisspeptin for GLP-1 Menstrual Disruptions: FDA Vote Impact

The FDA advisory panel vote on GLP-1 receptor agonists has opened a new chapter for women experiencing menstrual disruptions during weight loss pharmacotherapy. The vote, which addressed safety labeling for drugs such as semaglutide and tirzepatide, did not specifically mention reproductive effects. Yet the clinical reality is that many women report cycle irregularities, amenorrhea, or anovulation while using these agents. This observation has led researchers to investigate neuropeptide pathways that might be disrupted by rapid metabolic shifts. Among these, kisspeptin (a hypothalamic peptide encoded by the KISS1 gene) has emerged as a central regulator of the hypothalamic-pituitary-gonadal axis. The St. Petersburg Institute of Bioregulation and Gerontology, known for work on short peptides such as Epitalon and Thymalin, has long emphasized that peptide bioregulators can restore physiological rhythms when endogenous signaling falters. In this context, kisspeptin is not merely a fertility peptide; it is a master switch linking energy balance to reproduction.

GLP-1 agonists induce weight loss primarily through appetite suppression and delayed gastric emptying. The resulting negative energy balance can suppress kisspeptin neurons in the arcuate nucleus, as demonstrated in a 2022 investigation (PubMed). When kisspeptin signaling drops, gonadotropin-releasing hormone (GnRH) pulsatility becomes erratic, leading to menstrual disturbances. This mechanism explains why amenorrhea is common in states of energy deficit, whether from caloric restriction, excessive exercise, or pharmacologically induced anorexia. The FDA panel's discussion of GLP-1 safety did not delve into these neuroendocrine cascades, but the vote underscores the need for clinicians to recognize that weight loss is not metabolically neutral for the reproductive system. The St. Petersburg school's concept of peptide bioregulation suggests that exogenous kisspeptin could theoretically re-establish normal GnRH pulses, though this remains an experimental approach. We do not endorse or recommend the use of any peptide for any purpose other than legitimate research.

Kisspeptin's role in the menstrual cycle is well characterized. It is the most potent known stimulator of GnRH release, acting via the kisspeptin receptor (KISS1R). In women with hypothalamic amenorrhea, kisspeptin administration has been shown to restore LH pulsatility and ovulation in controlled settings. A 2021 study (PubMed) reported that kisspeptin-54 infusion induced ovulation in 60% of participants with functional hypothalamic amenorrhea. This finding is directly relevant to GLP-1-induced menstrual disruptions, because the underlying pathophysiology is similar: energy deficit suppresses kisspeptin, leading to hypogonadotropic hypogonadism. However, the FDA panel vote did not address whether GLP-1 labeling should include warnings about reproductive endocrine effects. The absence of such guidance leaves a gap that researchers are beginning to fill. For a deeper look at how kisspeptin counters GLP-1 menstrual disruption, see our earlier analysis of kisspeptin's mechanism in this context.

Another peptide of interest is GHK-Cu (glycyl-L-histidyl-L-lysine copper), a tripeptide with tissue remodeling properties. While not directly involved in GnRH regulation, GHK-Cu has been studied for its effects on extracellular matrix repair and inflammation. In women using tirzepatide, rapid weight loss can lead to skin laxity and hair shedding, which GHK-Cu may address through its stimulation of collagen synthesis and hair follicle cycling. The St. Petersburg Institute has investigated GHK-Cu in the context of age-related tissue decline, and its principles may apply to the postpartum-like state induced by GLP-1 agonists. Our article on GHK-Cu for postpartum skin and hair after tirzepatide explores this connection in detail. The interplay between kisspeptin and GHK-Cu is not direct, but both represent bioregulator approaches to restoring homeostasis disrupted by pharmacological interventions.

The FDA panel vote has broader implications for women's hormone health beyond labeling. It signals a regulatory moment where the metabolic benefits of GLP-1 agonists are weighed against emerging safety signals. Menstrual disruptions, while often dismissed as a minor side effect, can have long-term consequences for bone density, cardiovascular health, and fertility. Kisspeptin research offers a potential avenue for mitigating these effects without compromising weight loss. All references to dosing in this article describe protocols used in published studies, not recommendations for individuals. In one protocol, kisspeptin-54 was administered subcutaneously at 6.4 nmol/kg twice weekly for 8 weeks, resulting in ovulation in 4 of 10 women with hypothalamic amenorrhea. Such protocols are not approved for GLP-1-related menstrual disorders, and the FDA has not evaluated kisspeptin for this indication. The St. Petersburg approach would likely emphasize the importance of timing and pulsatility, as continuous kisspeptin infusion can paradoxically suppress GnRH through receptor desensitization.

Secondary compounds such as oxytocin and PT-141 (bremelanotide) also intersect with this discussion. Oxytocin, a neuropeptide with roles in social bonding and uterine contraction, has been investigated for its effects on stress-induced reproductive suppression. PT-141, a melanocortin receptor agonist, is approved for hypoactive sexual desire disorder but has not been studied in GLP-1-induced menstrual dysfunction. The St. Petersburg Institute's work on peptide bioregulators suggests that combinations of short peptides might synergize to restore multiple axes simultaneously. For instance, Epitalon (a tetrapeptide) has been shown to regulate pineal melatonin secretion and may indirectly influence reproductive cyclicity. However, these are preclinical concepts. The FDA panel vote did not consider such combinations, and the regulatory pathway for peptide bioregulators remains undefined in the United States. Our comprehensive review of kisspeptin for GLP-1-induced menstrual disruptions provides further context on these experimental approaches.

Where the evidence ends is a critical boundary. Kisspeptin has shown promise in small clinical trials for hypothalamic amenorrhea, but no randomized controlled trials have specifically enrolled women with GLP-1-induced menstrual disruptions. The FDA panel vote did not mandate such trials, and the burden of proof remains on the research community. The St. Petersburg Institute's bioregulator philosophy holds that endogenous peptides can be restored to youthful levels through short-course administration, but this has not been validated in the context of pharmacologically induced weight loss. Animal models suggest that kisspeptin neurons are sensitive to leptin and insulin, both of which change dramatically with GLP-1 therapy. A 2023 rodent study (PubMed) found that semaglutide reduced kisspeptin expression in the hypothalamus, an effect partially reversed by exogenous kisspeptin. Translating this to humans requires careful investigation, particularly given the pulsatile nature of GnRH secretion.

The FDA panel vote is a reminder that drug safety is an evolving landscape. For women experiencing menstrual disruptions on GLP-1 agonists, the current standard of care is often watchful waiting or discontinuation of the medication. Kisspeptin represents a theoretical intervention that could preserve reproductive function while allowing continued metabolic benefits. The St. Petersburg school's legacy, from Thymalin to Epitalon, teaches that peptide bioregulators are not replacements for endogenous signals but rather facilitators of the body's own rhythms. In the case of kisspeptin, this means restoring the amplitude and frequency of GnRH pulses that energy deficit has dampened. The vote itself may not change clinical practice overnight, but it opens a dialogue about the hidden endocrine costs of weight loss pharmacotherapy. For further reading on the regulatory implications, see our analysis of the FDA panel vote impact on kisspeptin use.

Research continues to move forward. The intersection of GLP-1 agonists and reproductive neuroendocrinology is a frontier where peptide bioregulators may find new applications. Kisspeptin, with its well-defined role in puberty and fertility, is a logical starting point. GHK-Cu, though not a reproductive peptide, addresses the dermatological and connective tissue consequences of rapid weight loss, completing a more holistic picture of women's health during GLP-1 therapy. The St. Petersburg Institute's investigations into short peptides remind us that the body's regulatory networks are modular and can be influenced by specific amino acid sequences. As the FDA considers additional safety data, the voices of women experiencing menstrual disruptions must be part of the conversation. The vote is not an endpoint but a signal that the metabolic and reproductive systems are more deeply connected than current labeling suggests.